

Product Name: Staurosporine Revision Date: 02/07/2023

Product Data Sheet

Staurosporine

Cat. No.: A8192

CAS No.: 62996-74-1 Formula: C28H26N4O3


M.Wt: 466.53

Synonyms:

Target: Tyrosine Kinase

Pathway: Broad Spectrum Protein Kinase Inhibitor

Storage: Store at -20°C



Solvent & Solubility

insoluble in H2O; insoluble in EtOH; ≥11.66 mg/mL in DMSO

Mass Solvent 1mg 5mg 10mg Preparing Concentration In Vitro Stock Solutions 1 mM 2.1435 mL 10.7174 mL 21.4348 mL 2.1435 mL 5 mM 0.4287 mL 4.2870 mL 10 mM 0.2143 mL 1.0717 mL 2.1435 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Protein kinase inhibitor,potent and cell permeable	
IC ₅₀ & Target	2 nM (PKCα), 5 nM (PKCγ), 4 nM (PKCη), 20 nM (PKCδ), 73 nM (PKCε), 1086 nM (PKCζ)	
	Cell Viability Assay	
	Cell Line:	A31 cell lines, CHO-KDR cell lines, Mo-7e cell lines and A431 cell lines.
	Preparation method:	The solubility of this compound in DMSO is <10 mM. General tips for obtaining
In Vitro		a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or
		shake it in the ultrasonic bath for a while.Stock solution can be stored below
		-20°C for several months.
	Reacting conditions:	24 h; IC50=0.08 mM (A31 cell lines), IC50=0.30 mM (Mo-7e cell lines),

		IC50=1.0 mM (CHO-KDR cell lines).
	Applications:	Staurosporine inhibited the ligand-induced autophosphorylation of the
		receptors for platelet-derived growth factor (PDGF) (IC50=0.08 mM) in A31 cell
		lines, stem cell factor (c-Kit, IC50=0.30 mM) in Mo-7e cell lines, and for VEGF
	G Juntan	(KDR, IC50=1.0 mM) in CHO-KDR cell lines, but did not affect the
	E Lipoce Inc.	ligand-induced autophosphorylation of the receptors for insulin, IGF-I, or
		epidermal growth factor (EGF) in A431 cell lines.
	Animal experiment	
	Animal models:	Athymic nude mice
	Dosage form:	75 mg/kg/day; oral taken.
	Applications:	The treatment with Staurosporine (75 mg/kg/day p.o.) completely inhibits the
		angiogenic response to VEGF, but not to bFGF. Thus, Staurosporine may
In Vivo		suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the
	40.	VEGF-R tyrosine kinases) in addition to directly inhibiting tumor cell
	in Unitrovia	proliferation (via its effects on PKCs). This anti-angiogenic action may
		contribute to the antimetastatic and broad antitumor activity displayed by
		Staurosporine, as well as the synergy with cytotoxic agents.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may
		slightly differ with the theoretical value. This is caused by an experimental
		system error and it is normal.

Product Citations

- 1. Chung HK, Zou X, et al."A compact synthetic pathway rewires cancer signaling to the apeutic effector release. Science." 2019 May 3;364(6439).PMID:31048459
- 2. Ashok Kumar, Ramon Edwin Caballero, et al. "Inhibitor of apoptosis, IAP, genes play a critical role in the survival of HIV-infected macrophages." BioRxiv. 2019 February 06.
- 3. Wang Y, Li Y, et al. "The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation." FASEB J. 2018 Sep 25:fj201800343R.PMID:30252535
- 4. Nissen SK, Pedersen JG, et al. "Multiple Homozygous Variants in the STING-Encoding TMEM173 Gene in HIV Long-Term Nonprogressors." J Immunol. 2018 May 15;200(10):3372-3382.PMID:29632140
- 5. Jarrett Smith, Geraldine Seydoux, et al. "Liquid-like P granules require ATP hydrolysis to avoid solidification." bioRxiv, Jan. 10, 2018.

See more customer validations on www.apexbt.com.

References

- [1] Andrejauskas-Buchdunger E, Regenass U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251[J]. Cancer research, 1992, 52(19): 5353-5358.
- [2] Fabbro D, Buchdunger E, Wood J, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an

anticancer agent[J]. Pharmacology & therapeutics, 1999, 82(2): 293-301.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com





